Several other indications are under study, including obstructive sleep apnea, MASLD, knee osteoarthritis, chronic kidney disease, and cardiovascular outcomes
Patients who notice significant mood changes after starting these medications should discuss them with their doctor

Key findings Related Stories Medically tailored grocery deliveries improve blood sugar control among diabetes patients Cleveland Clinic study links gut microbe byproduct to heart arrhythmia High doses of caffeine from energy drinks cause cardiovascular harm Within six months of starting GLP-1 therapy, the rate of hypotensive events increased from 8.7% to 10.2% The increased risk remained significant at 12 months, with hypotensive events rising from 13.6% to 14.3% Adults age 65 and older accounted for 53% of hypotensive events despite representing 37% of the study population Patients with Type 2 diabetes made up 75% of those experiencing hypotensive episodes but only 63% of the overall cohort In secondary analyses, the scientists found that weight loss alone did not explain the increased risk, suggesting other mechanisms of action may be at play Below is a Q&A with study senior author Dr

While these are different trials with different designs and not a direct head-to-head comparison, the data suggests retatrutide may deliver greater weight loss
As with most trending health innovations, separating marketing from measurable reality has become the key challenge for modern consumers
These are all desirable effects, but they create specific requirements around dosing speed, nutrition, and side effect management that differ from simpler compounds